Any current/future new fundraising through debt or equity?

Currently, Valiant Organics Limited does not have any immediate plans to raise more debt. Debt repayment is ongoing as per schedule, with about INR 40-45 crores expected to be repaid in the current financial year. The company plans to fund its current capex primarily through internal accruals without raising additional debt for now. If there is a future need to raise more debt, the company will consider that option at that time. Regarding equity, a subsidiary named Valiant Advanced Sciences is planning to raise funds through a greenfield project and has given intimation of a possible public is

Any current/future capex/capital investment/strategic investment?

Capex for FY '24 and FY '25 is projected around INR 100 crores to INR 110 crores annually, mainly for brownfield expansion, maintenance, and debottlenecking. No major new projects like PAP or Pharma Intermediates; focus on adding new products, especially in chlorination and ammonolysis segments. Some redevelopment and capacity improvement ongoing at Ahmedabad facility. Debottlenecking at Sarigam chlorination plant considered, but no specific capex or capacity numbers disclosed yet. Valiant Advanced Sciences, a subsidiary of Valiant Laboratories, plans a greenfield expansion project and is look

Future growth expectations in sales/revenue/volumes?

FY '24 revenue guidance on a standalone basis is around INR 1,200 crores, implying 30%-35% growth. Pharma Intermediates revenue expected to reach INR 55 crores in FY '24, phasing up to peak of INR 65-70 crores. PAP (paracetamol) volumes targeted to scale from ~400 tons/month to 500 tons/month by Q2 FY '24, then progressively to 700-750 tons/month by year-end, aiming for INR 250-300 crores revenue. Overall capacity utilization expected to increase in Sarigam unit from ~60% to 80-85% in the year, supporting agrochemical segment growth. New product additions in chlorination and ammonolysi

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margin guidance is targeted around 22% to 25% in the medium term, though unlikely to exceed 25% without significant new EBIT-accretive additions. (Page 18, 17) For FY24, the company expects EBITDA margins around 18% to 20%, aiming for standardized margins of 20%-25% eventually. (Pages 7, 5, 18) Revenue for standalone business is expected around INR 1,200 crores in FY24 with a 30%-35% growth assumption. (Page 11) Existing facility revenue potential is estimated between INR 1,300 crores to INR 1,500 crores in 2-3 years with no major capex. (Page 14) Capex of around INR 100-110 crores annu

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly state the current or expected order book value or pending orders quantitatively. Mihir Shah mentions challenges in getting certain products, like OAP, up and running, affecting timelines but not order backlog specifics. The Sarigam plant is operating well with chlorination demand stable and capacity at around 80-85%, indicating healthy order inflow. For PAP, volumes averaged around 400 tons per month in Q4, expected to scale to 700-750 tons per month by year-end, reflecting strong order demand. The company mentions quarterly contracts with customers, indicati

IN US

Sale is live|00:00:00left today

Valiant Organics LtdQ1 FY23Chemicals & Petrochemicals

Valiant Organics Ltd Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹280P/E: 27.6Market Cap: ₹831 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→FY '24 revenue guidance on a standalone basis is around INR 1,200 crores, implying 30%-35% growth.
→Pharma Intermediates revenue expected to reach INR 55 crores in FY '24, phasing up to peak of INR 65-70 crores.
→PAP (paracetamol) volumes targeted to scale from ~400 tons/month to 500 tons/month by Q2 FY '24, then progressively to 700-750 tons/month by year-end, aiming for INR 250-300 crores revenue.
→Overall capacity utilization expected to increase in Sarigam unit from ~60% to 80-85% in the year, supporting agrochemical segment growth.
→New product additions in chlorination and ammonolysis segments planned, supported by INR 100-110 crores annual capex, mostly for brownfield expansions and debottlenecking.
→Volume growth is expected month-on-month, but exact percentages are uncertain; some segments like dyes remain subdued.
→They target sustaining EBITDA margins around 20% in FY '24 with possible growth beyond 22-25% if significantly accretive products are added.

Margin guidance

Category 3

→EBITDA margin guidance is targeted around 22% to 25% in the medium term, though unlikely to exceed 25% without significant new EBIT-accretive additions. (Page 18, 17)
→For FY24, the company expects EBITDA margins around 18% to 20%, aiming for standardized margins of 20%-25% eventually. (Pages 7, 5, 18)
→Revenue for standalone business is expected around INR 1,200 crores in FY24 with a 30%-35% growth assumption. (Page 11)
→Existing facility revenue potential is estimated between INR 1,300 crores to INR 1,500 crores in 2-3 years with no major capex. (Page 14)
→Capex of around INR 100-110 crores annually planned mainly for brownfield expansions and maintenance; not for major capacity additions. (Pages 13, 14, 10)
→PAP plant scaling up, aiming for INR 250-300 crores revenue this year, with expectations to grow further. (Pages 10, 12)
→Profit cautious due to external factors but optimistic on gradual margin and revenue recovery over next 2-3 years. (Pages 16, 4)

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Currently, Valiant Organics Limited does not have any immediate plans to raise more debt.
→Debt repayment is ongoing as per schedule, with about INR 40-45 crores expected to be repaid in the current financial year.
→The company plans to fund its current capex primarily through internal accruals without raising additional debt for now.
→If there is a future need to raise more debt, the company will consider that option at that time.
→Regarding equity, a subsidiary named Valiant Advanced Sciences is planning to raise funds through a greenfield project and has given intimation of a possible public issue.
→The parent company itself has not mentioned any equity fundraising in the current discussions.

Order book

→The transcript does not explicitly state the current or expected order book value or pending orders quantitatively.
→Mihir Shah mentions challenges in getting certain products, like OAP, up and running, affecting timelines but not order backlog specifics.
→The Sarigam plant is operating well with chlorination demand stable and capacity at around 80-85%, indicating healthy order inflow.
→For PAP, volumes averaged around 400 tons per month in Q4, expected to scale to 700-750 tons per month by year-end, reflecting strong order demand.
→The company mentions quarterly contracts with customers, indicating ongoing order replenishment but without specific pending order data.
→The dialogue suggests steady demand in most segments, with caution on dyes and pigments due to weak industry conditions.
→Overall, while no exact order book figures are given, the company is scaling production progressively and managing orders through quarterly contracts.

Capex plans

Yes

→Capex for FY '24 and FY '25 is projected around INR 100 crores to INR 110 crores annually, mainly for brownfield expansion, maintenance, and debottlenecking.
→No major new projects like PAP or Pharma Intermediates; focus on adding new products, especially in chlorination and ammonolysis segments.
→Some redevelopment and capacity improvement ongoing at Ahmedabad facility.
→Debottlenecking at Sarigam chlorination plant considered, but no specific capex or capacity numbers disclosed yet.
→Valiant Advanced Sciences, a subsidiary of Valiant Laboratories, plans a greenfield expansion project and is looking to raise funds, possibly through a public issue.
→Capex mainly funded internally with no immediate plans to raise new debt, but options considered if needed.
→Ongoing loan repayments expected around INR 40-45 crores next year, reducing overall debt.

How does Valiant Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Valiant Organics Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Valiant Organics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio